Applied Therapeutics Inc.

1.33+0.0900+7.26%Vol 177.46K1Y Perf -92.00%
Aug 11th, 2022 16:00 DELAYED
BID1.24 ASK1.43
Open1.45 Previous Close1.24
Pre-Market- After-Market1.40
 - -  0.07 5.26%
Target Price
6.50 
Analyst Rating
Moderate Buy 2.00
Potential %
388.72 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/50/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/98/30 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/97/80 
Income Ranking
 —    -
Price Range Ratio 52W %
3.27 
Earnings Rating
Neutral
Market Cap34.89M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.29
Beta1.71 

Today's Price Range

1.291.45

52W Range

0.727719.14

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
1.53%
1 Month
33.55%
3 Months
-24.43%
6 Months
-42.92%
1 Year
-92.00%
3 Years
-85.65%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APLT1.330.09007.26
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.82-0.88-7.32
Q04 2021-1.22-1.0414.75
Q03 2021-0.99-1.09-10.10
Q02 2021-0.99-0.990.00
Q01 2021-1.06-1.005.66
Q04 2020-1.31-1.0619.08
Q03 2020-1.04-1.33-27.88
Q02 2020-0.72-1.27-76.39
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.9671.68Positive
9/2022 QR-0.4084.13Positive
12/2022 FY-3.13-552.08Negative
12/2023 FY-2.80-566.67Negative
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume177.46K
Shares Outstanding26.24K
Shares Float17.99M
Trades Count1.08K
Dollar Volume241.58K
Avg. Volume283.96K
Avg. Weekly Volume280.58K
Avg. Monthly Volume197.08K
Avg. Quarterly Volume374.21K

Applied Therapeutics Inc. (NASDAQ: APLT) stock closed at 1.33 per share at the end of the most recent trading day (a 7.26% change compared to the prior day closing price) with a volume of 177.46K shares and market capitalization of 34.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Applied Therapeutics Inc. CEO is Shoshana Shendelman.

The one-year performance of Applied Therapeutics Inc. stock is -92%, while year-to-date (YTD) performance is -85.14%. APLT stock has a five-year performance of %. Its 52-week range is between 0.7277 and 19.14, which gives APLT stock a 52-week price range ratio of 3.27%

Applied Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 0.64, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -98.39%, a ROC of -116.11% and a ROE of -123.23%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Applied Therapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Applied Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Applied Therapeutics Inc. is Moderate Buy (2), with a target price of $6.5, which is +388.72% compared to the current price. The earnings rating for Applied Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Applied Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Applied Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.00, ATR14 : 0.11, CCI20 : 108.85, Chaikin Money Flow : 0.09, MACD : 0.05, Money Flow Index : 73.55, ROC : 20.39, RSI : 55.18, STOCH (14,3) : 59.31, STOCH RSI : 0.43, UO : 58.23, Williams %R : -40.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Applied Therapeutics Inc. in the last 12-months were: Chids Mahadevan (Sold 905 shares of value $1 493 ), Riccardo Perfetti (Buy at a value of $125 797), Shoshana Shendelman (Buy at a value of $145 038)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
1.67
Moderate Buy
1.67

Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

CEO: Shoshana Shendelman

Telephone: +1 212 220-9226

Address: 545 Fifth Avenue, New York 10173, NY, US

Number of employees: 22

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

TipRanks News for APLT

Fri, 08 Apr 2022 03:35 GMT Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Vor Biopharma (VOR) and Eliem Therapeutics (ELYM)

- TipRanks. All rights reserved.

Sat, 12 Mar 2022 03:53 GMT Applied Therapeutics (APLT) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 02:06 GMT Applied Therapeutics (APLT) was Downgraded to a Hold Rating at Barclays

- TipRanks. All rights reserved.

News

Stocktwits